Fukuda, Keiji

Director_FK
Director and Clinical Professor

Division of Community Medicine and Public Health Practice

  • MD, MPH
Biography

Professor Keiji Fukuda joined the School of Public Health, The University of Hong Kong in December 2016 and became the School Director in 2017. Under him, the School has pioneered a holistic and multi-sectoral undergraduate programme on public health and development, established new research directions such as antimicrobial resistance and fostered collaborations and initiatives aimed at developing the next generation of health leadership. During Covid-19, he has been highly active speaking to international and local media and providing public health and scientific guidance to the Hong Kong Government and others.

He previously (2005 – 2016) worked at the World Health Organization (WHO) as Assistant Director-General for Health Security and Environment, Special Adviser to the Director-General on Pandemic Influenza, Special Adviser for Antimicrobial Resistance and Director of the Global Influenza Programme. He led global approaches to strengthen health security including the development and adoption of the Pandemic Influenza Preparedness Framework, implementation of the International Health Regulations as well as responses to events such as the emergence of influenza H5N1 and H7N9, the 2009 Pandemic influenza, MERS, Ebola and antimicrobial resistance (AMR). He led WHO’s international health diplomacy initiative that resulted in the 2016 historic Heads of State level meeting at the United Nations (UN) and a UN resolution on AMR. Professor Fukuda frequently was WHO’s main global media spokesperson on health security and AMR.

Before joining WHO, he worked at the U.S. Centers for Disease Control and Prevention Centers (CDC). As Chief of Epidemiology, Influenza Branch, he personally led CDC field teams that assisted Hong Kong during the 1997 avian influenza H5N1 outbreak and many other field investigations. He worked extensively in China on issues such as influenza surveillance, SARS and influenza H7N9. He helped develop new models combining epidemiological and laboratory data to improve US influenza surveillance and disease burden estimates, supported development of US influenza vaccination policy and led the international team that redefined the chronic fatigue syndrome. He is a physician and epidemiologist and received his BA from Oberlin College, MD from the University of Vermont, MPH from the University of California, Berkeley and EIS training at CDC.

Selected Publications
  1. Legido-Quigley, H., Asgari N., Teo Y. Y., Leung G. M., Oshitani H., Fukuda K., Cook, A.R., Hsu, L. Y., Shibuya, K., Heymann, D., Are high-performing health systems resilient against the COVID-19 epidemic?. Lancet. 2020 Mar 06. pii: S0140-6736(20)30551-1. doi: 10.1016/S0140-6736(20)30551-1. [Epub ahead of print]  [IF 59.10 (2018), rank 2/160 medicine, general and internal] [link]
  2. Monto, A. S. and Fukuda, K., Lessons from Influenza Pandemics of the last 100 Years. Clinical Infectious Diseases. 2019, 70(5): 951-957. [IF 9.06 (2018), rank 3/89 infectious diseases] [link]
  3. Limmathurotsakul, D., Dunachie S., Fukuda K., Feasey, N.A., Okeke, I.N., Holmes, A.H., Moore, C.E., Dolecek, C., van Doorn, H.R., Shetty, N., Lopez, A.D. and Peacock, S.J., Surveillance and Epidemiology of Drug Resistant Infections Consortium (SEDRIC), Improving the estimation of the global burden of antimicrobial resistant infections. The Lancet Infectious Diseases. 2019, v. 19 n. 11, p. E392-E398. [IF 27.52 (2018), rank 1/89 infectious diseases] [link]
  4. Hu Y.J., Ogyu A., Cowling B.J., Fukuda K. and Pang H.M.H., Available evidence of antibiotic resistance from extended-spectrum β-lactamase-producing Enterobacteriaceae in paediatric patients in 20 countries: a systematic review and meta-analysis, Bulletin of the World Health Organization. 2019, 97: 486-501B. [IF 6.82 (2018), rank 7/186 public, environmental & occupational health] [link]
  5. Hu Y.J., Cowling B.J. and Fukuda, K., What is missing in surveillance for control of antimicrobial resistance?, The Lancet Infectious Diseases. 2018, 18: 597-598. [IF 27.52 (2018), rank 1/89 infectious diseases] [link]
  6. Sprenger, M. and Fukuda, K., New mechanisms, new worries. Science. 2016; 351:1263-64. [IF 41.06 (2018), rank 2/69 multidisciplinary sciences] [link]
  7. Fukuda, K., Wang, R., Vallat, B. Naming diseases: First do no harm. Science. 2015, 348(6235): 643. [IF 41.06 (2018), rank 2/69 multidisciplinary sciences] [link]
  8. WHO Ebola Response Team. Ebola virus disease in West Africa – The first 9 month of the epidemic and forward projections New England Journal of Medicine. 2014; 371(16):1481-1495. [IF 70.67 (2018), rank 1/160 medicine, general & internal] [link]
  9. Briand S., and Fukuda, K., Avian influenza A (H5N1) and 2 fundamental questions. Editorial Journal of Infectious Diseases. 2009; 199 (12):1717-1719. [IF 5.05 (2018), rank 10/89 infectious diseases] [link]
  10. Fukuda, K.,and Kieny, M.P., Different Approaches to Influenza Vaccination. New England Journal of Medicine. 2006; 355:2586-2587. [IF 70.67, rank 1/160 medicine, general & internal] [link]
Back